On August 27, 2024 Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, reported that members of its management team will participate at two upcoming investor conferences and take 1×1 meetings (Press release, Mural Oncology, AUG 27, 2024, View Source [SID1234646120]). A webcast of both presentations will be available at ir.muraloncology.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley 22nd Annual Global Healthcare Conference

Fireside chat with Caroline Loew, Ph.D., CEO, Vicki Goodman, MD, Chief Medical Officer, and Adam Cutler, Chief Financial Officer

Date: Friday, September 6

Time: 1:50 p.m. ET

H.C. Wainwright 26th Annual Global Investment Conference

Presentation by Caroline Loew, Ph.D.

Date: Wednesday, September 11

Time: 9:30 a.m. ET